Company Update (NASDAQ:EDAP): EDAP Announces Sale of First Focal One(R) HIFU Device in North America


Edap Tms SA (NASDAQ:EDAP), the global leader in therapeutic ultrasound, announced the first sale of Focal One HIFU device to Jewish General HospitalMontreal, Canada. This sale occurs only two months after the Company gained Health Canada's approval to market its Focal One HIFU device for focal treatment of prostate cancer.

The Montreal Jewish General Hospital is one of the leading institutions for the treatment of Prostate Cancer in the Eastern part of CanadaThe Department of Uro-Oncology at Montreal Jewish General Hospital is headed by prominent urologist Franck Bladou, MD, also Professor of Surgery and Oncology at the prestigious McGill University.

Pr. Franck Bladou commented: "The concept of focal therapy for prostate cancer is a very promising treatment and appears to be the missing link between surveillance and robotic surgery for early stage prostate cancer patients. Focal One, together with its innovative MRI – ultrasound image fusing capabilities, is the only device capable of ablating the cancerous tissue within the prostate, using high-precision targeting, in a non-invasive way, sparing the rest of the prostate, and therefore minimizing the risk of side effect. The Jewish General Hospital is proud to be the first clinical site in the Americas to offer this therapeutic option to its patients."

Marc Oczachowski, EDAP's Chief Executive Officer, added, "We are very pleased to achieve this first sale of Focal One in Canada only two months after receiving marketing approval from Health Canada. This is an important validation of our innovative device dedicated to Focal therapy of prostate cancer from one of the leading hospitals in the region. Importantly, it allows us to further establish our HIFU technology in North America and offer this non-invasive focal solution to a larger number of prostate cancer patients in need."

Additionally, the Company announced that it plans to issue a press release announcing its financial results for the fourth quarter and twelve months ended December 31, 2014 on April 1, 2015 after the close of market. The Company previously announced that the press release would be issued during pre-market hours on April 2, 2015. The conference call to discuss fourth quarter and full-year 2014 results will take place as originally scheduled, at 8:30 a.m. ET on April 2, 2015. To participate in the call, please dial 1-888-348-6419 in the U.S., or 1-412-902-4235 internationally. The conference ID number is 10062222. A live webcast of the conference call will be available on the investor relations page of the Company's corporate website at www.edap-tms.com.(Original Source)

Shares of EDAP TMS S.A. closed yesterday at $3.72 . EDAP has a 1-year high of $6.05 and a 1-year low of $1.15. The stock's 50-day moving average is $3.65 and it's 200-day moving average is $2.44.

EDAP TMS SA develops, produces and markets minimally invasive medical devices, mainly for urological diseases. Its activity is organized in two divisions: HIFU and UDS.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts